Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Targeted Search
Clinical Trials Search Results
Query: "AREA[SponsorSearch](Fujian Cancer Hospital)"
Count: 126
Selected: 0
| NCT ID | Title |
|---|
| NCT04421469 | Triprilimab(JS001) and Chemotherapy Combined With Local Treatment for Multiple Metastatic NPC | ||
| NCT04319471 | Sufficient Chemotherapy Combine With Maintenance Chemotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma | ||
| NCT04220528 | Radical Radiotherapy and Chemotherapy Combined With Maintenance Chemotherapy in the Treatment of Stage N3 NPC | ||
| NCT03666221 | Nimotuzumab for Recurrent Nasopharyngeal Carcinoma | ||
| NCT05699655 | Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer | ||
| NCT05675033 | Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma | ||
| NCT05664139 | Recombinant Human Adenovirus Type 5 Injection Combined With PD-1 Monoclonal Antibody and Nab-paclitaxel in the Treatment of Patients With Liver Metastases From Malignant Melanoma | ||
| NCT05663177 | Almonertinib Plus Metronomic Oral Vinorelbine | ||
| NCT05649618 | TIL Cells for the Treatment of the Advanced Solid Tumors Patients | ||
| NCT05648994 | TCR-T Cells for the Treatment NY-ESO-1-positive Advanced Solid Tumors | ||
| NCT05640726 | The First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard Therapy | ||
| NCT05628610 | Tislelizumab Combined With Chemotherapy or Radiotherapy in the Treatment of Advanced or Recurrent Metastatic Elderly Esophageal Cancer | ||
| NCT05624099 | Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer. | ||
| NCT05597527 | Fluzopari Combined With Apatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer | ||
| NCT05595889 | Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung Cancer | ||
| NCT05561023 | Phase Ⅰa Clinical Study of Hawthorn Red Pigment Combined With Standard Analgesic for Refractory Cancer Pain | ||
| NCT05519956 | Elective Level Ib Irradiation in Nasopharyngeal Carcinoma Patients Based on the International Guidelines | ||
| NCT05497076 | the Efficacy and Safety of Dalpiciclib Combined With Third-generation EGFR-TKI in Patients With EGFR Mutation and Meningial Metastasis in Non-small Cell Lung Cancer Progressing Through Third-generation TKI and Platinum-containing Two-drug Chemotherapy | ||
| NCT05479240 | Short-range Radiotherapy Sequential Tislelizumab Combined With Chemotherapy Versus Long Range Radiotherapy and Chemotherapy Combined With Tislelizumab Neoadjuvant Therapy for Locally Advanced Rectal Cancer | ||
| NCT05335460 | To Determine the Efficacy and Safety of Envafolimab Combined With XELOX for Locally Advanced Colon Cancer | ||
| NCT05319639 | Phase I Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab | ||
| NCT05314101 | TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal Cancer | ||
| NCT05266820 | Trifluridine/Tipiracil (TAS-102) With or Without Thalidomide for the Treatment of Metastatic Colorectal Cancer | ||
| NCT05223088 | Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer | ||
| NCT05192681 | Tislelizumab as Cross-line Treatment for Advanced NSCLC | ||
| NCT05131243 | the Role of ctDNA in Predicting the Recurrence Risk of Colorectal Cancer | ||
| NCT05049811 | Effects of Mobile Medicine on Cancer Patients | ||
| NCT05035446 | Short-term Outcomes of SILS+1 Versus CLS for Distal Gastric Cancer | ||
| NCT05019690 | Apatinib Combined With Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer | ||
| NCT05007145 | PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Subjects With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma | ||
| NCT05001360 | Study of FMT Combined With Nivolumab in Gastric Cancer | ||
| NCT04955886 | Surufatinib Combined With Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma | ||
| NCT04844645 | Using Mini Program for Self-management VS Conventional Pharmaceutical Care for Cancer Pain | ||
| NCT04785768 | IV PCA With or Without Continuous Dose vs Oral Opioid to Maintain Analgesia for Severe Cancer Pain After Successful Titration | ||
| NCT04764006 | Surufatinib Combined With Sintilimab for Advanced MSS-Type Colorectal Cancer : a Phase II Study | ||
| NCT04745741 | Evaluating the Rationality of the International Guideline About Selective Coverage of Level Ib in CTV With NPC | ||
| NCT04734249 | Second-line Surufatinib Combined With Chemotherapy in Advanced CRC | ||
| NCT04613804 | Toripalimab as Maintenance Therapy in Patients With Driver-gene Negative Advanced NSCLC After First-line Chemotherapy | ||
| NCT04533243 | Opioid Titration With 12.5 ug/h Fentanyl Transdermal Patch vs Orally Morphine for Opioid-naïve Patients With Moderate Cancer Pain | ||
| NCT04387266 | To Evaluate the Efficacy and Feasibility of Modified Reduce-volume Target IMRT in the Treatment of Patients With Non-metastatic NPC | ||
| NCT04354961 | Almonertinib Versus Paclitaxel Plus Carboplatin as First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic Pulmonary Adenosquamous Carcinoma （ARISE） | ||
| NCT04243954 | Intravenous vs Oral Analgesia in Cancer Patients With Severe Pain After Successful Titration | ||
| NCT04174339 | PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Advanced Gastric Cancer | ||
| NCT04155671 | POF Versus FOLFOX Plus IP Paclitaxel in AGC | ||
| NCT04149015 | Neoadjuvant POF in the Treatment of Locally Advanced Gastric Cancer | ||
| NCT04121039 | Study of the Apatinib Combine With POF Versus POF in Gastric Cancer | ||
| NCT04089657 | Apatinib Plus Sintilimab in Advanced Gastric Cancer Refractory to at Least Two Previous Chemotherapy Regimens | ||
| NCT03872635 | Effects of Anesthesia on Tumor Immunity and Insulin Resistance During Perioperative Period | ||
| NCT03788226 | A Randomized Phase III Study Comparing POF With SOX/CAPOX/FOLFOX as a Postoperative Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer | ||
| NCT03788174 | Apatinib Combined With POF for Second-line Treatment of Gastric Adenocarcinoma |
